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Background: A challenge for drug of abuse testing is presented by ‘designer drugs’, compounds typically discovered
by modifications of existing clinical drug classes such as amphetamines and cannabinoids. Drug of abuse screening
immunoassays directed at amphetamine or methamphetamine only detect a small subset of designer amphetamine-
like drugs, and those immunoassays designed for tetrahydrocannabinol metabolites generally do not cross-react with
synthetic cannabinoids lacking the classic cannabinoid chemical backbone. This suggests complexity in understanding
how to detect and identify whether a patient has taken a molecule of one class or another, impacting clinical care.
Methods: Cross-reactivity data from immunoassays specifically targeting designer amphetamine-like and synthetic
cannabinoid drugs was collected from multiple published sources, and virtual chemical libraries for molecular similarity
analysis were built. The virtual library for synthetic cannabinoid analysis contained a total of 169 structures, while the
virtual library for amphetamine-type stimulants contained 288 compounds. Two-dimensional (2D) similarity for each
test compound was compared to the target molecule of the immunoassay undergoing analysis.
Results: 2D similarity differentiated between cross-reactive and non-cross-reactive compounds for immunoassays
targeting mephedrone/methcathinone, 3,4-methylenedioxypyrovalerone, benzylpiperazine, mephentermine, and
synthetic cannabinoids.
Conclusions: In this study, we applied 2D molecular similarity analysis to the designer amphetamine-type stimulants
and synthetic cannabinoids. Similarity calculations can be used to more efficiently decide which drugs and metabolites
should be tested in cross-reactivity studies, as well as to design experiments and potentially predict antigens that
would lead to immunoassays with cross reactivity for a broader array of designer drugs.
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Immunoassays (antibody-based assays) are widely em-
ployed for drug of abuse/toxicology screening on urine or
other bodily fluids. Immunoassays may utilize polyclonal
or monoclonal antibodies, with a trend towards monoclo-
nal antibody-based designs [1,2]. Many hospital-based
clinical laboratories perform immunoassay drug of abuse
screening panels targeted towards commonly abused
drugs or drug classes such as amphetamines, benzodiaze-
pines, cannabinoids, cocaine, methadone, opiates, and* Correspondence: mkrasows@healthcare.uiowa.edu
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article, unless otherwise stated.phencyclidine [3,4]. In addition to immunoassays, mass
spectrometry-based methods such as gas chromatography/
mass spectrometry (GC/MS) or liquid chromatography-
tandem mass spectrometry (LC/MS/MS) can provide spe-
cific and definitive identification of drugs and drug metab-
olites; such methods are often used for confirmation of
positive immunoassay screening results or for detection of
drugs known to be undetectable or not readily detected by
immunoassays [4-6]. While an increasing number of clin-
ical laboratories are using mass spectrometry-based assays
for drug of abuse testing, relatively few hospital-based
clinical laboratories have the capability to do this testing
with a rapid turnaround time. Thus, many clinical labora-
tories refer confirmatory testing to off-site regional orry Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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around time is too slow to aid in real-time patient man-
agement [3,4]. Consequently, immunoassays continue to
be used in many settings for drug of abuse testing.
A challenge for drug of abuse testing is presented by
what are widely termed ‘designer drugs’, a heterogeneous
group of psychoactive compounds typically discovered
by modifications of existing clinical drug classes such as
amphetamines [7-10]. Two current categories of de-
signer drugs are the amphetamine-type stimulants and
the synthetic cannabinoids, each of which comprises a
chemically diverse set of compounds (see Figures 1 and 2
for representative compounds and their chemical struc-
tures). Designer drugs may be sold over the counter or via
the internet using deceptive descriptors such as “plant
fertilizer”, “incense”, “potpourri”, “research chemicals”, or
“bath salts”. Further, many compounds are initially legal
due to the regulatory challenge of trying to outlaw the
large numbers of possible drug analogs that may be syn-
thesized and distributed; authorities throughout the world
have struggled with this issue [11,12]. In 2011, the UnitedFigure 1 Representative chemical structures of amphetamine-type dr
MDPV, 3,4-methylenedioxypyrovalerone; MDPBP, 3′,4′-methylenedioxy-α-py
Additional file 1.States Drug Enforcement Agency (DEA) temporarily
classified mephedrone, 3,4-methylenedioxypyrovalerone
(MDPV), and methylone as Schedule 1 drugs, a designa-
tion that indicates drugs with no accepted medical use
and very high abuse liability [13]. Additionally, in June of
2012, the United States Congress approved Schedule 1
status for an additional 26 designer amphetamine-type
stimulants and synthetic cannabinoids [14]. Clearly, due
to the diversity of amphetamine-type and cannabinoid
chemistry, there are likely many more structures that
will ultimately require restricted status.
The amphetamine-type stimulants are related to am-
phetamine, methamphetamine, and 3,4-methylenedioxy-
N-methylamphetamine (MDMA; “ecstasy”) [15]. Designer
amphetamine-type drugs represent hundreds of individual
compounds (many of which have detailed descriptions of
chemical synthesis and psychoactive effects in two books
by Shulgin and Shulgin [16,17]) and can be further broken
down into sub-categories such as β-keto amphetamines,
piperazines, tryptamines, and 2C compounds (see Figure 1
for examples). Methylone, MDPV, and mephedrone areugs. Abbreviations: MDMA, 3,4-methylenedioxy-N-methamphetamine;
rrolidinobutiophenone. Additional descriptions of compounds are in
Figure 2 Representative chemical structures of cannabinoids. Detailed names for compounds are in Additional file 2.
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referred to as “bath salts” and have received the most inter-
est from the media and law enforcement [18,19].
The synthetic cannabinoids are similarly diverse and
were originally examined for scientific and therapeutic
applications (see Figure 2 for representative chemical
structures) [20-22]. Like tetrahydrocannabinol (THC)
from cannabis, the synthetic cannabinoids interact with
cannabinoid receptors in the nervous system, producing
a variety of psychoactive effects [23]. However, clandes-
tine laboratories began to synthesize synthetic cannabi-
noids for use in products often marketed as “legal highs”
[24]. Two of the most commonly abused synthetic can-
nabinoids are 1-naphthyl-(1-pentylindol-3-yl)methanone
(JWH-018; named after discoverer John W. Huffman)
and 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl) (JWH-250)
[25]. As shown in Figure 2, some synthetic cannabinoidssuch as JWH-018 (a naphthoylindole) differ considerably
in chemical structure from the “classic” cannabinoid
chemical backbone of THC, while other compounds such
as HU-210 (1,1-dimethylheptyl-11-hydroxy-THC) are an-
alogs of THC.
Detection of designer amphetamine-type stimulants
and synthetic cannabinoids in the clinical and forensic
toxicology settings presents a complicated challenge
[15]. There is a growing literature on detection of these
designer molecules by mass spectrometry-based methods
(see for example [26-40]). Drug of abuse screening immu-
noassays based on amphetamine, methamphetamine, and/
or MDMA as the target molecule(s) cross-react with only
a small subset of designer amphetamine-like drugs and are
thus unreliable for detection of designer amphetamine-like
drugs [41-45]. Immunoassays designed for THC metabo-
lites (e.g., 11-nor-Δ9 THC-9-carboxylic acid, “9-carboxy-
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nabinoids that do not share the classic cannabinoid back-
bone found in THC [15]. This suggests complexity in
understanding how to detect and correctly identify
whether a patient has taken a molecule of one class or an-
other, and this ultimately impacts clinical care.
Recently, enzyme-linked immunosorbent assays (ELISAs)
for “bath salts” [45] and synthetic cannabinoids [46] have
been developed and analyzed for cross-reactivity. The use
of immunoassays such as ELISA for detection of designer
drugs raises the question of how well such assays will de-
tect a variety of compounds while avoiding false positives
caused by cross-reactivity with unrelated compounds.
Two-dimensional (2D) molecular similarity analysis
represents one of many potential cheminformatics ap-
proaches to this problem. In four previous publications,
we provided proof of concept for the use of computa-
tional 2D or 3D similarity methods to predict cross-
reactivity of compounds for immunoassays used for drug
of abuse screening [44,47,48] and therapeutic drug moni-
toring [49] immunoassays. In these studies, 2D similarity
using MDL keys/fingerprints were superior to 2D simi-
larity using FCFP_6 fingerprints (one of many fingerprint
types) and 3D pharmacophores in predicting cross-
reactivity of immunoassays [44,47-49]. By comparing
empirical data obtained from cross-reactivity studies with
the molecular modeling studies, our published data indi-
cate that 2D molecular similarity methods perform well
in predicting cross-reactivity of drugs to existing drug of
abuse screening immunoassays. Further, these methods
can help prioritize compounds for cross-reactivity testing
and identify novel cross-reacting compounds [48]. In this
study, we now apply 2D molecular similarity analysis to
the designer amphetamine-type stimulants and synthetic
cannabinoids.
Results
Similarity analysis of amphetamine-like drugs
Mephedrone (4-methylmethcathinone) and MDPV are
two common designer amphetamine-like drugs. Randox
markets one ELISA assay targeting mephedrone/meth-
cathinone and another assay targeting MDPV. Figure 3A
shows the 2D similarity of methcathinone to 287 other
amphetamine-like drugs (note: mephedrone and meth-
cathinone have 2D similarity of 1.0 to each other due to
how close they are in structure; see Additional file 1 for
complete similarity and cross-reactivity data). The only
molecules with 2D similarity of 0.6 or greater to meth-
cathinone are other cathinone derivatives (e.g., methyleth-
cathinone, 3-fluoromethcathinone). The 2C and tryptamine
series of drugs all possess 2D similarity of less than 0.4 to
methcathinone. Figure 3B shows the 2D similarity of com-
pounds with cross-reactivity > 0.8% of methcathinone in
the Randox Mephedrone/Methcathinone assay (cross-reactivity data is from both the assay package insert and
publication by Swortwood et al. [45]) compared to non-
cross-reactive compounds. None of the 2C and tryptamine
compounds tested cross-react with the mephedrone/
methcathinone ELISA. Six of the eight cross-reactive com-
pounds have 2D similarity to methcathinone of greater
than 0.68, whereas only two of twenty-five non-cross-
reactive compounds have 2D similarity that high. Figure 3B
also shows 2D similarity to methcathinone of the “un-
tested” compounds (i.e., those compounds in Additional
file 1 whose cross-reactivity has not been reported).
Figure 3C shows ROC curve analysis of how well 2D simi-
larity as a “diagnostic test” predicts cross-reactivity of
compounds for the Mephedrone/Methcathinone assay.
The area under the curve (AUC) is 0.942.
Figure 3D shows the 2D similarity of MDPV to 287
other amphetamine-like drugs (complete dataset is in
Additional file 1). Only 23 other compounds in this
dataset possess 2D similarity of 0.6 or greater to MDPV.
Only four compounds (other than MDPV itself ) cross-
react with the Randox MDPV ELISA (cross-reactivity
data is from both the assay package insert and publica-
tion by Swortwood et al. [45]). Figure 3E shows the 2D
similarity of compounds with cross-reactivity > 0.8% of
methcathinone in the Randox MDPV assay. All four
cross-reacting compounds have 2D similarity greater
than 0.6 to MDPV. Figure 3E also shows 2D similarity
to MDPV of “untested” compounds. Figure 3F shows the
ROC curve analysis of how well 2D similarity predicts
cross-reactivity of compounds for the MDPV assay. The
AUC is 0.987. Table 1 lists true positives, false positives,
true negatives, and false negatives at select cutoffs for
the assays depicted in Figure 3.
Benzylpiperazine and mephentermine are two amphet-
amine-like drugs that may be abused [7,15]. Neogen mar-
kets separate ELISA assays for these two drugs. Figure 4A
shows the 2D similarity of benzylpiperazine to 287 other
amphetamine-like drugs (complete dataset is in Additional
file 1). The only compounds with 2D similarity of 0.6 or
greater are other piperazines, a single tryptamine com-
pound (N,N-tetramethylenetryptamine), and phencyclid-
ine. Of compounds tested for cross-reactivity, only two
piperazine compounds (other than benzylpiperazine itself )
cross-react with the Neogen Benzylpiperazine ELISA
(Figure 4B; cross-reactivity data is from both the assay
package insert and publication by Swortwood et al. [45]).
Figure 4C shows the 2D similarity of mephentermine to
287 other amphetamine-like drugs (complete dataset is in
Additional file 1). The only compounds with 2D similarity
to mephentermine of 0.6 or greater are phentermine,
methamphetamine, amphetamine, p-methoxyethylamphe-
tamine, 4-methylthioamphetamine, and ethylampheta-
mine. Only two compounds (methamphetamine and
MDMA) cross-react with the Neogen Mephentermine
Figure 3 Similarity analyses of the “bath salts” and prediction of immunoassay cross-reactivity. Similarity analyses of mephedrone/
methcathinone and 3,4-methylenedioxypyrovalerone (MDPV) – (A) 2D similarity of methcathinone to 287 amphetamine-like compounds. (B) 2D
similarity of compounds that are cross-reactive, non-cross-reactive, or untested for the Randox Mephedrone/Methcathinone ELISA. (C) ROC curve
analysis for the ability of 2D similarity to predict the cross-reactivity of compounds for the Randox Mephedrone/Methcathinone ELISA. The AUC is
0.942. Maximum efficiency of 88.9% is achieved at a cutoff of 0.455 (sensitivity = 87.5% and specificity = 89.3% at that cutoff). (D) 2D similarity of
MDPV to 287 amphetamine-like compounds. (E) 2D similarity of compounds that are cross-reactive, non-cross-reactive, or untested for the Randox
MDPV ELISA. (F) ROC curve analysis for the ability of 2D similarity to predict the cross-reactivity of compounds for the Randox MDPV ELISA. The
AUC is 0.987. Maximum efficiency of 97.2% is achieved at a cutoff of 0.673 (sensitivity = 80.0% and specificity = 100.0% at that cutoff).
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less cross-reactivity relative to mephentermine [45].
MDMA cross-reacts but has low 2D similarity (0.421).
Table 1 lists true positives, false positives, true negatives,
and false negatives at select cutoffs for the assays depicted
in Figure 4.Similarity analysis of synthetic cannabinoids
The synthetic cannabinoids are a diverse group of mole-
cules with a nomenclature that can be confusing. Hun-
dreds of compounds are in the JWH (John W. Huffman)
series, although many have not yet been identified as
drugs of abuse [22,24,25]. Additional file 2 has 43 JWH
Table 1 True positives, false positives, true negatives, and false negatives for the immunoassays using selected 2D
similarity cutoffs
Assay 2D similarity cutoff True positives False positives True negatives False negatives
Randox Mephedrone/Methcathinone 0.680 6 2 25 2
0.390 8 6 19 0
Randox MDPV 0.630 5 0 30 0
Neogen Benzylpiperazine 0.730 3 1 28 0
Neogen Mephentermine 0.840 2 0 26 1
0.420 3 7 19 0
JWH-018 Direct ELISA 0.673 27 21 44 3
JWH-250 Direct ELISA 0.875 3 0 92 0
Immunalysis MKT-1030 0.673 13 0 6 4
Immunalysis MKT-1032 0.673 15 0 3 4
Neogen Synthetic Cannabinoids 0.673 23 0 4 8
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32 associated metabolites. Even within the JWH series
are different classifications including naphthoylindoles
(e.g., JWH-018), naphthylmethylindoles (e.g., JWH-175),
and phenylacetylindoles (e.g., JWH-201). There are severalFigure 4 Similarity analyses of benzylpiperazine (BZP) and mephente
similarity of BZP to 287 amphetamine-like compounds. (B) 2D similarity of
the Neogen Benzylpiperazine Forensic ELISA. (C) 2D similarity of mephente
compounds that are cross-reactive, non-cross-reactive, or untested for theother series of synthetic cannabinoids including the AM,
UR, RCS, and XLR series; some of these are closely related
to compounds in the JWH series [24,25].
Figure 5 shows plots of the 2D similarity of 168 other
compounds compared to four cannabinoid targets, withrmine and prediction of immunoassay cross-reactivity. (A) 2D
compounds that are cross-reactive, non-cross-reactive, or untested for
rmine to 287 amphetamine-like compounds. (D) 2D similarity of
Neogen Mephentermine Forensic ELISA.
Figure 5 Similarity comparisons of cannabinoids. Test compounds are divided into broad categories (JWH series, AM/UR/RCS/XLR series,
other synthetic cannabinoids not possessing the chemical backbone of THC, cannabinoids sharing chemical backbone of THC, endogenous
eicosanoid cannabinoids, and non-cannabinoids). (A) 2D similarity of the N-pentanoic acid metabolite of JWH-018 to 168 other compounds.
(B) 2D similarity of the N-butanoic acid metabolite of JWH-073 to 168 other compounds. (C) 2D similarity of the N-4-hydroxy metabolite of JWH-
250 to 168 other compounds. (D) 2D similarity of 9-carboxy-THC to 168 other compounds.
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series, (ii) AM/UR/RCS/XLR series, (iii) all other syn-
thetic cannabinoids not possessing the classic cannabin-
oid backbone of THC, (iv) cannabinoids sharing classic
cannabinoid backbone of THC, (v) endogenous eicosanoid
cannabinoids, and (vi) non-cannabinoids]. Figure 5A-C
uses metabolites of JWH-018, JWH-073, and JHW-250,
respectively, as target molecules for the 2D similarity ana-
lysis. These metabolites were chosen because they are de-
tected well by at least one commercial immunoassay for
which cross-reactivity data is available (some compounds
are the calibrator for the assay). Figure 5D uses 9-carboxy-
THC as the target compound for 2D similarity analysis.
Figure 5A shows 2D similarity analysis using the N-
pentanoic acid metabolite of JWH-018 (calibrator com-
pound for the Immunalysis MKT-1030 and MKT-1032
assay kits) as the target. Within the JWH series (includ-
ing metabolites), all but one other compound (JWH-
175) have 2D similarity to the JWH-018 metabolite of
0.6 or greater. Outside the JWH series, a number of
other compounds have high similarity. These include the
N-4-hydroxy metabolite of AM-2201 (similarity = 0.851)
and WIN 55,212-2/WIN 55,212-3 (both have similarity =0.638). The compounds closely related to THC have low
2D similarity to the JWH-018 metabolite, as do the two
endogenous cannabinoids (all with 2D similarity less than
0.420). A similar pattern is seen in Figure 5B with the
JWH-073N-butanoic acid metabolite (a metabolite
detected well by the Immunalysis MKT-1030 and MKT-
1032 kits). Figure 5C shows the 2D similarity to the N-4-
hydroxy metabolite of JWH-250 (a calibrator for a
JWH-250 ELISA that has been described in a publication
by Arntson et al. [46]). The overall pattern of similarity is
roughly that of JWH-018 and JWH-073 in Figure 5A and
5B, with the exception that pravadoline, metabolites of
RCS-4, and cannabipiperidiethanone have high simi-
larity to the JWH-250 metabolite (see Figure 2 for
chemical structures). Figure 5D shows similarity of 9-
carboxy-THC to 168 other compounds. Outside of
compounds sharing the classic cannabinoid backbone
of THC, the THC metabolite has generally low similar-
ity to other cannabinoids. CB-25 and CB-52, which are
in essence hybrids of THC and the endogenous canna-
binoid anandamide, possess low 2D similarity (0.407
and 0.400, respectively) despite sharing some core fea-
tures with THC.
Figure 6 Similarity analyses and prediction of immunoassay
cross-reactivity for synthetic cannabinoids of the JWH series.
Similarity analyses for ELISA assays of JWH-018 and JWH-250 - (A) 2D
similarity of compounds that are cross-reactive (divided into sub-
categories of 25% or greater and 1-24%), non-cross-reactive, or
untested for a JWH-018 Direct ELISA [46]. The 5-hydroxy metabolite
of JWH-018 is used as the target for similarity analysis. (B) ROC curve
analysis for the ability of 2D similarity to predict the cross-reactivity
of compounds for the JWH-018 ELISA. The AUC is 0.987. Maximum
efficiency of 82.1% is achieved at a cutoff of 0.673 (sensitivity =
93.8% and specificity = 56.7% at that cutoff). (C) 2D similarity of
compounds that are cross-reactive, non-cross-reactive, or untested
for a JWH-250 Direct ELISA [46]. The 4-hydroxy metabolite of JWH-
250 is used as the target for similarity analysis.
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ELISA which uses the 5-hydroxy metabolite of JWH-018
as the calibrator [46]. Using the published cross-
reactivity data, the 2D similarity to the JWH-018 metab-
olite is displayed in Figure 6A for compounds with 25%
or more cross-reactivity, 1-24% cross-reactivity, less than
1% cross-reactivity, or “untested” (i.e., using all remaining
compounds from Additional file 2). All compounds with
1% or more cross-reactivity have similarity to the JWH-
018 metabolite of 0.623 or greater. In contrast, similarity
of 0.623 or higher was seen in only 30 of the 65 com-
pounds that displayed cross-reactivity less than 1%.
Figure 6B shows the ROC curve analysis of how well 2D
similarity performed as a “diagnostic test” predicting
cross-reactivity of the JWH-018 ELISA. The AUC is 0.859.
Figure 6C shows cross-reactivity data of a JWH-250
ELISA which uses the 4-hydroxy metabolite of JWH-250
as the calibrator [46]. In this assay, only three metabolites
other than the calibrator had cross-reactivity greater than
1%. The lowest 2D similarity for these three cross-reactive
compounds was 0.875. Table 1 lists true positives, false
positives, true negatives, and false negatives at select cut-
offs for the assays depicted in Figure 6.
Figure 7A and 7C show cross-reactivity of the Immu-
nalysis MKT-1030 and MKT-1032 synthetic cannabinoid
assays, respectively, sorted by 2D similarity to the N-
pentanoic acid metabolite of JWH-018 (calibrator for the
assays). The highest 2D similarity of the non-cross-
reactive compounds reported in the MKT-1030 and
MKT-1032 package inserts to the JWH-018 metabolite
was 0.667. For MKT-1030, only 1 of 14 compounds with
25% or more cross-reactivity and 2 of 12 compounds
with 1-24% cross-reactivity had 2D similarity of 0.667 or
lower (Figure 7A). For the MKT-1032 assay, only 4 of 18
compounds with 25% or more cross-reactivity had 2D
similarity of 0.667 or lower (Figure 7C). Figure 7B shows
the ROC curve analysis of how well 2D similarity per-
formed as a diagnostic test predicting cross-reactivity of
the MKT-1030 assay.
Figure 7 Prediction of synthetic cannabinoid immunoassay cross-reactivity using 2D-similarity analysis. Similarity analyses for synthetic
cannabinoid immuonassays- (A) 2D similarity of compounds that are cross-reactive (divided into sub-categories of 25% or greater and 1-24%),
non-cross-reactive, or untested for the Immunalysis MKT-1030 synthetic cannabinoid assay. The N-pentanoic acid metabolite of JWH-018 is used
as the target for similarity analysis. (B) ROC curve analysis for the ability of 2D similarity to predict the cross-reactivity of compounds for the MKT-
1030 assay. The AUC is 0.840. Maximum efficiency of 86.7% is achieved at a cutoff of 0.673 (sensitivity = 83.3% and specificity = 100% at that
cutoff). (C) 2D similarity of compounds that are cross-reactive (divided into sub-categories of 25% or greater and 1-24%), non-cross-reactive, or
untested for the Immunalysis MKT-1032 synthetic cannabinoid assay. The N-pentanoic acid metabolite of JWH-018 is used as the target for similarity
analysis. (D) 2D similarity of compounds that are cross-reactive (divided into sub-categories of 50% or greater and 1-49%), non-cross-reactive, or
untested for the Neogen Synthetic Cannabinoids assay. The N-pentanoic acid metabolite of JWH-018 is used as the target for similarity analysis. (E) 2D
similarity of compounds that are cross-reactive (divided into sub-categories of 25% or greater and 1-24%) or untested for the Randox Synthetic
Cannabinoids assay. The N-pentanoic acid metabolite of JWH-018 is used as the target for similarity analysis.
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nabinoids assay. For this assay, the highest 2D similarity
of the non-cross-reactive compounds to the N-pentanoic
acid metabolite of JWH-018 was 0.667. Only 4 of 24compounds with 50% or more cross-reactivity had a 2D
similarity that low. 3-(1-naphthoyl)-1H-indole was un-
usual in having low 2D similarity to the JWH-018 me-
tabolite (0.455) yet was cross-reactive in the Neogen and
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shows data for the Randox Synthetic Cannabinoids
(Spice) ELISA kit. In this assay, all cross-reactive com-
pounds had 2D similarity to the N-pentanoic acid
metabolite of JWH-018 of 0.650 or higher. Only 2 of 7
non-cross-reactive compounds had similarity that high.
Figure 7 also includes 2D similarity comparisons to un-
tested compounds found in Additional file 2. Table 1
lists true positives, false positives, true negatives, and
false negatives at select cutoffs for the assays depicted in
Figure 7.
Discussion
Previously we have shown in several studies that 2D mo-
lecular similarity methods perform well in predicting
cross-reactivity of drugs to existing drug of abuse
screening immunoassays [44,47,49]. In this study, we
have compared published empirical data obtained from
various cross-reactivity studies using MDL keys and 2D
molecular similarity data in order to illustrate that such
cheminformatics studies can predict cross-reactivity of
designer amphetamine-type stimulants and synthetic
cannabinoids. We have also been able to measure mo-
lecular similarity for many more compounds than have
been tested experimentally for assay cross-reactivity in-
cluding a large dataset of FDA approved drugs and their
metabolites. In general, these compounds display 2D
similarities below those of compounds cross-reactive
with the immunoassays. We propose that molecular
similarity can help differentiate between likely cross-
reactive and non-cross reactive compounds to immuno-
assays for methcathinone/mephedrone, MDPV, and
synthetic cannabinoids. This could be useful for select-
ing and classifying additional compounds that may also
require DEA Schedule I status classification [13,14].
The evaluation and application of cheminformatics
approaches to this research area has been limited
[44,47-49]. We have previous compared FCFP_6 finger-
prints (one of many fingerprint types) and 3D pharmaco-
phores with MDL keys/fingerprints [44,48,49]. The goal of
the current study was not to perform an exhausting ana-
lysis of fingerprints or similarity measures. Future studies
could evaluate commercial and open source fingerprints
(some of which may encode 3D information) as well as ap-
proaches to normalize, standardize, or combine data from
different approaches using methods such as the belief the-
ory [50] or data fusion [51-54]. In addition, approaches
other than ROC curves could be used to evaluate the simi-
larity and experimental cross-reactivity data [55].
A limitation of the similarity approaches is that these
cannot account for the complex three-dimensional mo-
lecular interactions inherent in antibody-antigen bind-
ing. 3-(1-naphthoyl)-1H-indole is an example of a
compound with low 2D similarity to the targetcompounds of an immunoassay, but which nonetheless
has good cross-reactivity. 3-(1-naphthoyl)-1H-indole
possesses the same overall shape as the JWH series of
compounds but is missing a nitrogen atom along with
the aliphatic tail (Figure 2). Compounds such as 3-(1-
naphthoyl)-1H-indole may provide insight into the min-
imal sub-structural features important for antibody-drug
interactions. An additional limitation of the similarity
methods are that these do not account for concentration-
dependence of cross-reactivity. There is very limited data
on pharmacokinetics of synthetic cannabinoids and
amphetamine-type drugs, especially at doses used to
achieve intoxication. Even compounds with low cross-
reactivity may be detected by an assay if present in urine
or other body fluid at high concentrations.
As more experimental cross-reactivity data is generated
for each immunoassay, it may be possible to use this to
build machine learning models (e.g., Bayesian or Support
Vector Machine) in order to predict this property for a
new compound. The advantage of this approach is that it
is not dependent on molecular similarity to a single mol-
ecule but instead uses the empirical data for a range of
compounds for that subject of the immunoassay.
Experimental
Cross-reactivity data
Cross-reactivity data was found in multiple sources in-
cluding published literature and package inserts for
marketed assays. Randox Toxicology Limited (Crumlin,
Antrim, United Kingdom) markets two ELISA kits for
presumptive identification of “bath salts”, one targeting
mephedrone/methcathinone (Mephedrone/Methcathi-
none ELISA, product # MD3475) and the other directed
at detection of MDPV (MDPV ELISA, product # MD3476).
Randox also markets an ELISA assay for synthetic canna-
binoids [Synthetic Cannabinoids (Spice) ELISA, product #
SC3474]. Immunalysis, Inc. (Pomona, CA, USA) markets
two assays for synthetic cannabinoids [K2 (Synthetic
Cannabinoids-1) Direct ELISA kit, product # MKT-1030;
and Synthetic Cannabinoids (Spice, K2) Homogeneous
Enzyme Immunoassay (HEIA), product # MKT-1032].
Neogen Corporation (Lexington, KY, USA) markets ELI-
SAs for synthetic cannabinoids [Synthetic Cannabinoids
(SPICE) ELISA kit], benzylpiperazine (Benzylpiperazine
Forensic ELISA), and mephentermine (Mephentermine
Forensic ELISA). Two publications report extensive cross-
reactivity testing of immunoassays targeted at synthetic
cannabinoids [46] and amphetamine-type stimulants [45].
For the Neogen Synthetic Cannabinoids ELISA, Ran-
dox Synthetic Cannabinoids ELISA, the Immunalysis
synthetic cannabinoids assays, and two synthetic canna-
binoids assays reported in the literature by Arntson et al.
[46], there is extensive cross-reactivity data covering a
wide range of values. Following an approach used in our
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data for these assays in different groups based on degree
of cross-reactivity. The exact subdivisions are somewhat
arbitrary (especially given the wide and varying numeric
cross-reactivity values for these assays) but do provide a
relative scale of strong versus weak cross-reactivity. All
data is presented in dot plots that allow for visualization
of the entire set of data.
Virtual chemical libraries
The virtual chemical libraries (Additional files 1 and 2)
used for molecular similarity analysis were built using
parent drugs and metabolites identified in the package
inserts and literature references cited in the previous
paragraph and from additional published literature
on pharmacokinetics of amphetamine-type stimulants
[44,56-62] and synthetic cannabinoids [25,30,33,40,63-69].
The virtual library for synthetic cannabinoid analysis
contained a total of 169 structures (including two en-
dogenous eicosanoid cannabinoids – anandamide and 2-
arachnidonylglycerol [70,71]); and (ten non-cannabinoids
which have been tested for cross-reactivity in synthetic
cannabinoid immunoassays [46]). The virtual library for
amphetamine-type stimulants contained 288 compounds.
Many of the amphetamine-type stimulants are described
in two books by Shulgin and Shulgin [16,17] and the
number used in these books is also included in Additional
file 1 for cross-reference. Also included in the virtual
chemical library was a database of Food and Drug Ad-
ministration (FDA)-approved drugs (n = 676) derived
from the Clinician’s Pocket Drug Reference [72], supple-
mented with drugs of abuse and drug metabolites (n =
110). This database has been used in four of our previous
publications [48,49,73,74].
Conclusions
In conclusion, we propose that similarity calculations
can be used to more efficiently decide which drugs and
metabolites should be tested in cross-reactivity studies,
as well as to design experiments and potentially predict
antigens that would lead to immunoassays with cross-
reactivity for a broader array of designer drugs. As new
analogs are synthesized and distributed, similarity calcu-
lations can guide and prioritize cross-reactivity studies.
This very basic method may form the foundation for ap-
plying more complex cheminformatics approaches as
more immunoassay cross-reactivity data is generated.
Methods
2D molecular similarity analysis
Comparison of similarity of test molecules to the target
compounds of the immunoassays in question used 2D
similarity analysis, which determines the similarity be-
tween molecules independent of any in vitro data[75-77]. These methods have been applied in previous
publications on cross-reactivity of drug of abuse and
therapeutic drug monitoring immunoassays [44,47-49].
2D similarity searching used the “find similar molecules
by fingerprints” protocol in Discovery Studio versions
2.5.5 and 3.5 (Accelrys, Inc., San Diego, California,
USA). MDL public keys (a specific 2D similarity algo-
rithm) were used with an input query and with the
Tanimoto similarity coefficient as the output (the coeffi-
cient ranges from 0 to 1, with 1 being maximally similar
and 0 being maximally dissimilar; a comparison of a
compound with itself or to a very closely related mol-
ecule can produce an output of 1). It should be noted
that 2D similarity algorithms with this particular finger-
print method do not distinguish between diastereomers
and enantiomers (although there are 2D similarity
methods that can include stereoisomer information in
generating fingerprint bits). There is very little experimen-
tal data on cross-reactivity of stereoisomers for the de-
signer drugs and metabolites analyzed in this report. 2D
similarity for each test compound was compared to the
target molecule of the immunoassay undergoing analysis.
Statistical analysis
Statistical analyses using receiver operating characteristic
(ROC) curve analysis were carried out in EP Evaluator re-
lease 9 (Data Innovations, South Burlington, VA, USA).
Sensitivity was defined as: (number of true positives)/
(number of true positives + number of false negatives).
Specificity was defined as: (number of true negatives)/
(number of true negatives + number of false positives). Ef-
ficiency was defined as: (number of true positives + num-
ber of true negatives)/(number of true positives + number
of true negatives + number of false positives + number of
false negatives). ROC curve analysis plots the true positive
rate (sensitivity) on the y-axis versus the false positive rate
(1-specificity). EP Evaluator calculates the true and false
positive rate at a range of thresholds for the 2D similarity
in discriminating experimental determined assay cross-
reactivity (positive) compared to lack of cross-reactivity
(negative). ROC curve analysis was only performed if
there were five or more cross-reactive compounds for a
given assay. EP Evaluator does not allow for ROC curve
analysis if less than five datapoints are available in either
the positive or negative groups. This is to avoid erroneous
conclusions based on ROC curve analysis of samples with
small study size [78].
Additional files
Additional file 1: Cross-Reactivity and Similarity Data for
Amphetamine-like Compounds: Contains common and scientific
names and SMILES identifiers for compounds, along with cross-
reactivity data of immunoassays and 2D similarity measures for the
amphetamine-like compounds analyzed in this study.
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